Please assess the completion status of the following clinical trial:

Trial Title: Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects with type 2 diabetes mellitus~* On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization~* Body mass indices \> 25 and \< 45 kg/m2~* Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening~* Fasting C-peptide levels ≥ 0.2 nmol/L at screening~* Subject with a history of hypertension must be on a stable antihypertensive treatment (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first dose of investigational product~* Other criteria may apply~Exclusion Criteria~* Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus~* Subject has had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening~* Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥ 155 mmHg (confirmed by a repeat assessment) at screening~* Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening~* Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives (whichever is longer), prior to receiving the first dose of investigational product.~* Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half lives (whichever is longer) prior to receiving the first dose of investigational product~* Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AMG 151 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).